Masataka Kawana, MD
Cardiovascular Disease (Cardiology) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 6
Offices
6 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kawana’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A114281 · Current
Licensed to practise in California · since 2010 · expires 2028-09-30 · Brown University Program in Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$91,949
Medicare paid this office $91,949 for 1,006 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $22,822 | $105 |
| Critical care, first 30-74 minutes | 35 | $20,948 | $184 |
| Long return visit (40+ min) | 89 | $12,274 | $122 |
| Return visit (30+ min) | 60 | $5,144 | $70 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 630 | $5,023 | $7 |
See all 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 61 | $22,822 | $105 |
| Critical care, first 30-74 minutes | 35 | $20,948 | $184 |
| Long return visit (40+ min) | 89 | $12,274 | $122 |
| Return visit (30+ min) | 60 | $5,144 | $70 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 630 | $5,023 | $7 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $4,400 | $137 |
| Return visit (30+ min) | 26 | $3,033 | $108 |
| Hospital discharge day management, more than 30 minutes | 30 | $3,012 | $100 |
| New patient visit (60+ min) | 17 | $2,445 | $144 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 104 | $2,273 | $22 |
| Evaluation of lower heart chamber assist device | 16 | $1,590 | $33 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 22 | $1,245 | $28 |
| Programming of multiple lead implantable defibrillator system | 16 | $813 | $45 |
| Programming of dual lead implantable defibrillator system | 12 | $650 | $46 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 18 | $253 | $14 |
Who their Medicare patients are
1,006 Original Medicare patients in 2024. Average age 74 · Under 65 13% · 85 and older 17% · Women 49% · Also on Medicaid 31% · Health risk score 2.48. Sicker patients than 9 in 10 peers; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Heart failure 55% · Coronary heart disease 53% · Chronic kidney disease 49% · Atrial fibrillation 48% · Diabetes 43% · Depression 26% · COPD 24% · Cancer 21% · Dementia 19% · Stroke 19%.
The office billed $558,523, Medicare allowed $121,486 and paid $91,949; for 1,674 services of 31 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,006 | 1,674 | 74 | 2.48 | $558,523 | $91,949 |
| 2023 | 1,225 | 2,039 | 74 | 2.45 | $508,090 | $96,737 |
| 2022 | 684 | 1,340 | 73 | 2.34 | $627,951 | $97,354 |
| 2021 | 219 | 818 | 72 | 3.07 | $504,893 | $92,579 |
| 2020 | 256 | 588 | 71 | 2.58 | $203,107 | $41,174 |
| 2019 | 374 | 1,049 | 71 | 2.92 | $300,353 | $70,909 |
| 2018 | 85 | 410 | 62 | 3.46 | $147,667 | $32,357 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $26,623 | $109 |
| Critical care, first 30-74 minutes | 20 | $15,003 | $192 |
| Long return visit (40+ min) | 83 | $12,983 | $127 |
| Return visit (30+ min) | 85 | $9,565 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 895 | $7,861 | $7 |
| New patient visit (60+ min) | 31 | $4,900 | $158 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,798 | $160 |
| Hospital discharge day management, more than 30 minutes | 40 | $4,605 | $107 |
| Evaluation of lower heart chamber assist device | 20 | $2,600 | $36 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 93 | $2,297 | $24 |
| Programming of multiple lead implantable defibrillator system | 20 | $1,366 | $53 |
| Programming of dual lead implantable defibrillator system | 12 | $833 | $49 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 11 | $545 | $34 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 21 | $455 | $22 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 18 | $260 | $14 |
2022: 11 services
| Critical care, first 30-74 minutes | 42 | $39,592 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $16,711 | $93 |
| Long return visit (40+ min) | 67 | $10,927 | $124 |
| Return visit (30+ min) | 81 | $8,405 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,507 | $180 |
| Hospital discharge day management, more than 30 minutes | 41 | $3,947 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 421 | $3,717 | $7 |
| New patient visit (60+ min) | 14 | $2,366 | $169 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 60 | $1,593 | $25 |
| Programming of multiple lead implantable defibrillator system | 17 | $1,207 | $57 |
| Evaluation of lower heart chamber assist device | 16 | $784 | $34 |
2021: 11 services
| Critical care, first 30-74 minutes | 47 | $28,503 | $199 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $22,561 | $95 |
| Long return visit (40+ min) | 75 | $13,083 | $126 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,590 | $183 |
| Return visit (30+ min) | 45 | $5,083 | $83 |
| Hospital discharge day management, more than 30 minutes | 42 | $4,428 | $98 |
| Evaluation of lower heart chamber assist device | 12 | $2,176 | $36 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,045 | $120 |
| New patient visit (60+ min) | 12 | $2,008 | $167 |
| Programming of multiple lead implantable defibrillator system | 11 | $826 | $59 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 18 | $366 | $20 |
2020: 9 services
| Critical care, first 30-74 minutes | 13 | $9,431 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 32 | $9,279 | $91 |
| Long return visit (40+ min) | 58 | $8,018 | $90 |
| Return visit (30+ min) | 44 | $3,783 | $70 |
| Evaluation of lower heart chamber assist device | 18 | $1,641 | $36 |
| Hospital discharge day management, more than 30 minutes | 13 | $1,208 | $93 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 112 | $1,049 | $8 |
| Programming of multiple lead implantable defibrillator system | 11 | $701 | $50 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 24 | $598 | $22 |
2019: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $25,985 | $92 |
| Long return visit (40+ min) | 119 | $16,623 | $96 |
| Evaluation of lower heart chamber assist device | 36 | $10,073 | $41 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $5,426 | $181 |
| New patient visit (60+ min) | 25 | $3,598 | $144 |
| Hospital discharge day management, more than 30 minutes | 24 | $2,540 | $94 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 179 | $1,467 | $8 |
| Return visit (30+ min) | 22 | $1,414 | $61 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 26 | $15,354 | $94 |
| Evaluation of lower heart chamber assist device | 23 | $5,078 | $41 |
| Long return visit (40+ min) | 37 | $4,489 | $100 |
| Return visit (30+ min) | 19 | $1,413 | $71 |
Medicaid work
$28,193 in 2024
Medicaid paid $28,193 for 879 billed services this clinician did in 2024, up to 135 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 217 | $18,837 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 545 | $4,639 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 76 | $2,695 |
| Return visit (30+ min) | 16 | $1,083 |
| 1ST HOSP IP/OBS HIGH 75 | 12 | $691 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 13 | $247 |
| 2024 | 879 | 6 | 135 | $28,193 |
| 2023 | 1,203 | 6 | 242 | $23,445 |
| 2022 | 614 | 3 | 101 | $14,187 |
| 2021 | 189 | 3 | 22 | $7,671 |
| 2020 | 129 | 1 | 81 | $1,794 |
| 2019 | 192 | 3 | 55 | $3,880 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 227 | $11,102 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 850 | $8,338 |
| Return visit (30+ min) | 41 | $1,540 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 39 | $1,190 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 12 | $698 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 34 | $578 |
2022
| Long return visit (40+ min) | 161 | $8,202 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 409 | $4,427 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 44 | $1,559 |
2021
| Long return visit (40+ min) | 61 | $3,876 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 116 | $3,156 |
| Hospital inpatient or observation discharge day management; more than 30 minutes on the date of the encounter | 12 | $640 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 129 | $1,794 |
2019
| Long return visit (40+ min) | 29 | $1,653 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 121 | $1,447 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 42 | $779 |
Drugs they prescribed that Part D paid
$918,075
Pharmacies billed $918,075 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,747) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,285 generic and 462 brand-name prescriptions · $918,075 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Camzyos | 23 | $183,527 | $7,979 |
| Jardiance | 126 | $158,535 | $1,258 |
| Eliquis | 117 | $152,048 | $1,300 |
| Entresto | 90 | $128,449 | $1,427 |
| Everolimus | 17 | $47,635 | $2,802 |
See all 31 drugs
| Camzyos | 23 | $183,527 | $7,979 |
| Jardiance | 126 | $158,535 | $1,258 |
| Eliquis | 117 | $152,048 | $1,300 |
| Entresto | 90 | $128,449 | $1,427 |
| Everolimus | 17 | $47,635 | $2,802 |
| Farxiga | 32 | $29,159 | $911 |
| Potassium Chloride | 43 | $7,102 | $165 |
| Bumetanide | 53 | $4,256 | $80 |
| Sirolimus | 12 | $2,079 | $173 |
| Metoprolol | 99 | $1,810 | $18 |
| Carvedilol | 156 | $1,594 | $10 |
| Mycophenolate Mofetil | 12 | $1,283 | $107 |
| Eplerenone | 16 | $1,255 | $78 |
| Losartan | 81 | $1,173 | $14 |
| Rosuvastatin | 67 | $949 | $14 |
| Spironolactone | 111 | $870 | $8 |
| Amiodarone | 27 | $850 | $31 |
| Digoxin | 42 | $838 | $20 |
| Atorvastatin | 83 | $783 | $9 |
| Tacrolimus | 12 | $739 | $62 |
| Famotidine | 23 | $534 | $23 |
| Hydralazine | 30 | $457 | $15 |
| Clopidogrel | 22 | $439 | $20 |
| Furosemide | 70 | $289 | $4 |
| Isosorbide Mononitrate Er | 22 | $261 | $12 |
| Nitroglycerin | 25 | $243 | $10 |
| Lisinopril | 35 | $243 | $7 |
| Warfarin | 15 | $239 | $16 |
| Ezetimibe | 17 | $152 | $9 |
| Amlodipine Besylate | 40 | $134 | $3 |
| Hydrochlorothiazide | 19 | $105 | $6 |
Year by year
| 2024 | 1,747 | 215 | 0% (0) | 26% | $918,075 |
| 2023 | 1,463 | 219 | None | None | $763,511 |
| 2022 | 1,188 | 184 | 0% (0) | 20% | $359,583 |
| 2021 | 1,249 | 182 | None | 17% | $264,604 |
| 2020 | 1,201 | 174 | None | None | $246,904 |
| 2019 | 1,005 | 166 | None | 18% | $154,114 |
| 2018 | 161 | 59 | None | 16% | $27,375 |
| 2017 | 53 | 16 | None | 23% | $12,075 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Vyndamax | 13 | $263,085 | $20,237 |
| Eliquis | 95 | $129,029 | $1,358 |
| Entresto | 79 | $126,764 | $1,605 |
| Jardiance | 59 | $72,641 | $1,231 |
| Farxiga | 27 | $40,721 | $1,508 |
| Xarelto | 16 | $24,399 | $1,525 |
| Everolimus | 11 | $8,667 | $788 |
| Sirolimus | 26 | $6,600 | $254 |
| Bumetanide | 60 | $6,235 | $104 |
| Potassium Chloride | 48 | $5,586 | $116 |
| Metoprolol | 83 | $3,318 | $40 |
| Rosuvastatin | 53 | $2,085 | $39 |
| Carvedilol | 107 | $1,927 | $18 |
| Atorvastatin | 66 | $1,880 | $28 |
| Losartan | 77 | $1,519 | $20 |
| Isosorbide Dinitrate | 12 | $1,358 | $113 |
| Hydralazine | 38 | $1,007 | $26 |
| Spironolactone | 77 | $997 | $13 |
| Mycophenolate Mofetil | 18 | $915 | $51 |
| Clopidogrel | 23 | $745 | $32 |
| Digoxin | 24 | $712 | $30 |
| Ezetimibe | 14 | $705 | $50 |
| Lisinopril | 48 | $674 | $14 |
| Furosemide | 51 | $601 | $12 |
| Amlodipine Besylate | 31 | $592 | $19 |
| Buspirone | 13 | $501 | $39 |
| Amiodarone | 20 | $473 | $24 |
| Famotidine | 23 | $458 | $20 |
| Warfarin | 21 | $418 | $20 |
| Pantoprazole | 21 | $325 | $15 |
| Isosorbide Mononitrate Er | 17 | $283 | $17 |
| Levothyroxine | 14 | $265 | $19 |
| Hydrochlorothiazide | 18 | $110 | $6 |
2022: 28 drugs
| Entresto | 54 | $70,021 | $1,297 |
| Eliquis | 55 | $68,906 | $1,253 |
| Farxiga | 33 | $44,655 | $1,353 |
| Jardiance | 38 | $39,514 | $1,040 |
| Potassium Chloride | 24 | $8,188 | $341 |
| Bumetanide | 55 | $7,518 | $137 |
| Eplerenone | 15 | $2,109 | $141 |
| Metoprolol | 73 | $2,075 | $28 |
| Hydralazine | 55 | $2,028 | $37 |
| Atorvastatin | 48 | $1,636 | $34 |
| Mycophenolate Mofetil | 20 | $1,565 | $78 |
| Ezetimibe | 19 | $1,487 | $78 |
| Carvedilol | 102 | $1,426 | $14 |
| Losartan | 46 | $1,044 | $23 |
| Valsartan | 11 | $1,022 | $93 |
| Spironolactone | 63 | $813 | $13 |
| Rosuvastatin | 18 | $806 | $45 |
| Amlodipine Besylate | 41 | $703 | $17 |
| Furosemide | 41 | $515 | $13 |
| Lisinopril | 35 | $429 | $12 |
| Isosorbide Mononitrate Er | 11 | $357 | $32 |
| Clopidogrel | 23 | $357 | $16 |
| Digoxin | 18 | $330 | $18 |
| Amiodarone | 16 | $308 | $19 |
| Famotidine | 24 | $306 | $13 |
| Warfarin | 15 | $198 | $13 |
| Buspirone | 11 | $180 | $16 |
| Pantoprazole | 13 | $73 | $6 |
2021: 34 drugs
| Entresto | 60 | $71,118 | $1,185 |
| Eliquis | 54 | $66,019 | $1,223 |
| Jardiance | 17 | $25,494 | $1,500 |
| Farxiga | 12 | $18,505 | $1,542 |
| Potassium Chloride | 32 | $6,198 | $194 |
| Tacrolimus | 20 | $5,980 | $299 |
| Sirolimus | 20 | $5,602 | $280 |
| Bumetanide | 50 | $5,094 | $102 |
| Isosorbide Dinitrate | 17 | $4,205 | $247 |
| Eplerenone | 23 | $2,453 | $107 |
| Carvedilol | 128 | $1,825 | $14 |
| Hydralazine | 31 | $1,516 | $49 |
| Metoprolol | 45 | $1,386 | $31 |
| Mycophenolate Mofetil | 20 | $1,229 | $61 |
| Losartan | 59 | $1,062 | $18 |
| Digoxin | 19 | $779 | $41 |
| Ezetimibe | 21 | $714 | $34 |
| Spironolactone | 61 | $696 | $11 |
| Furosemide | 42 | $520 | $12 |
| Isosorbide Mononitrate Er | 15 | $497 | $33 |
| Atorvastatin | 33 | $493 | $15 |
| Famotidine | 37 | $479 | $13 |
| Amlodipine Besylate | 29 | $316 | $11 |
| Pravastatin | 18 | $306 | $17 |
| Clopidogrel | 16 | $295 | $18 |
| Nitroglycerin | 14 | $274 | $20 |
| Lisinopril | 36 | $273 | $8 |
| Sertraline | 15 | $272 | $18 |
| Doxepin | 14 | $264 | $19 |
| Amiodarone | 14 | $216 | $15 |
| Tamsulosin | 14 | $212 | $15 |
| Warfarin | 17 | $189 | $11 |
| Buspirone | 11 | $138 | $13 |
| Hydrochlorothiazide | 18 | $79 | $4 |
2020: 35 drugs
| Eliquis | 54 | $55,105 | $1,020 |
| Entresto | 44 | $44,234 | $1,005 |
| Jardiance | 32 | $27,646 | $864 |
| Sirolimus | 29 | $25,944 | $895 |
| Atovaquone | 21 | $15,307 | $729 |
| Bumetanide | 43 | $3,237 | $75 |
| Tacrolimus | 18 | $2,751 | $153 |
| Potassium Chloride | 18 | $1,988 | $110 |
| Eplerenone | 13 | $1,765 | $136 |
| Carvedilol | 102 | $1,422 | $14 |
| Metoprolol | 42 | $986 | $23 |
| Losartan | 74 | $934 | $13 |
| Digoxin | 22 | $881 | $40 |
| Hydralazine | 31 | $815 | $26 |
| Mycophenolate Mofetil | 18 | $802 | $45 |
| Rosuvastatin | 32 | $776 | $24 |
| Spironolactone | 54 | $626 | $12 |
| Isosorbide Mononitrate Er | 13 | $521 | $40 |
| Warfarin | 25 | $494 | $20 |
| Atorvastatin | 41 | $452 | $11 |
| Ondansetron Odt | 12 | $395 | $33 |
| Furosemide | 28 | $376 | $13 |
| Clopidogrel | 14 | $355 | $25 |
| Gabapentin | 20 | $330 | $16 |
| Pravastatin | 20 | $328 | $16 |
| Amiodarone | 17 | $313 | $18 |
| Lisinopril | 45 | $312 | $7 |
| Doxepin | 14 | $291 | $21 |
| Tamsulosin | 11 | $206 | $19 |
| Acyclovir | 13 | $174 | $13 |
| Sertraline | 19 | $159 | $8 |
| Amlodipine Besylate | 22 | $144 | $7 |
| Famotidine | 19 | $142 | $7 |
| Duloxetine | 11 | $95 | $9 |
| Trazodone | 13 | $70 | $5 |
2019: 25 drugs
| Entresto | 23 | $29,252 | $1,272 |
| Eliquis | 30 | $16,847 | $562 |
| Sirolimus | 15 | $14,574 | $972 |
| Vascepa | 20 | $6,331 | $317 |
| Tacrolimus | 19 | $3,175 | $167 |
| Bumetanide | 23 | $2,808 | $122 |
| Potassium Chloride | 26 | $1,004 | $39 |
| Rosuvastatin | 28 | $859 | $31 |
| Hydralazine | 38 | $745 | $20 |
| Losartan | 53 | $679 | $13 |
| Carvedilol | 53 | $678 | $13 |
| Pravastatin | 42 | $646 | $15 |
| Digoxin | 17 | $576 | $34 |
| Mycophenolate Mofetil | 22 | $544 | $25 |
| Metoprolol | 18 | $512 | $28 |
| Lisinopril | 55 | $443 | $8 |
| Spironolactone | 56 | $428 | $8 |
| Warfarin | 31 | $377 | $12 |
| Isosorbide Mononitrate Er | 15 | $305 | $20 |
| Furosemide | 48 | $274 | $6 |
| Atorvastatin | 16 | $260 | $16 |
| Pantoprazole | 27 | $232 | $9 |
| Amlodipine Besylate | 37 | $170 | $5 |
| Gabapentin | 12 | $137 | $11 |
| Trazodone | 11 | $118 | $11 |
Money from drug and device companies
$1,243 in 2025
| 2025 | 2 | 2 | $1,200 | $1,243 |
| 2023 | 1 | 1 | None | $202 |
| 2022 | 1 | 1 | None | $125 |
| 2019 | 2 | 3 | $1,800 | $1,903 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Edwards Lifesciences | None | $1,200 | 1 payment
|
| CVRx | Barostim Neo System | $43 | 1 payment
|
See all 2 published payments
| CVRx | Meals · 2025-07-14 | Barostim Neo System | $43 |
| Edwards Lifesciences | Consulting · 2025-02-10 | None | $1,200 |
See earlier years (2023, 2022, 2019)
2023: $202
| Edwards Lifesciences | None | $202 | 1 payment
|
2022: $125
| E.R. Squibb & Sons L.L.C. | None | $125 | 1 payment
|
2019: $1,903
| Nihon Kohden America | None | $1,800 | 2 payments
|
| Medtronic Vascular | Heartware Hvad | $103 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Nihon Kohden America, Inc. · Pilot Study for Evaluation of Ezcvp in Heart Failure Patient · 2020 | Their institution | $48,994 |
| Nihon Kohden America, Inc. · Pilot Study for the Evaluation of Ezcvp in Heart Failure Patients · 2022 | Their institution | $14,004 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1518263029
- Licence
- CA A114281California A114281: Current · expires 2028-09-30
- Trained
- Warren Alpert Medical School of Brown University, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RA0001X (207RA0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-01-31
- NPI last updated
- 2024-04-22
- NPI record certified
- 2024-04-22
This is when the NPI record was last certified, not a medical board exam.